Pharmacogenetics of tenofovir treatment

Pharmacogenomics

Volumn 10, Issue 10, 2009, Pages 1675-1685

  Rodriguez Novoa, Sonia ^a   Labarga, Pablo ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

HIV; Multidrug resistant proteins; Nephrotoxicity; Organic anion transporters; Pharmacogenetics; Tenofovir

Indexed keywords

ADEFOVIR; ATAZANAVIR; CIDOFOVIR; DIDANOSINE; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; TENOFOVIR DISOPROXIL;

AREA UNDER THE CURVE; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG MEGADOSE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HUMAN; KIDNEY TUBULE; NEPHROTOXICITY; NONHUMAN; PHARMACOGENETICS; PROTEIN LOCALIZATION; REVIEW;

ADENINE; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HIV-1; HUMANS; KIDNEY DISEASES; KIDNEY TUBULES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS; PHOSPHONIC ACIDS; POLYMORPHISM, GENETIC;

EID: 70649087107     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.115     Document Type: Review

References (66)

1. Gupta S, Mamlin B, Johnson C, Dollins M, Topf J, Dube M: Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin. Nephrol. 61(1), 1-6 (2004). (Pubitemid 38100837)
2. Palella F, Baker R, Moorman A et al.: Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J. Acquir. Immune Defic. Syndr. 43(1), 27-34 (2006). (Pubitemid 44306484)
3. Nelson M, Katlama C, Montaner J et al.: The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21(10), 1273-1281 (2007). (Pubitemid 46883481)
4. Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V: Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS 18(6), 960-963 (2004).
5. Coca S, Perazella M: Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am. J. Med. Sci. 324(6), 342-344 (2002). (Pubitemid 36109329)
6. Karras A, Lafaurie M, Furco A et al.: Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin. Infect. Dis. 36(8), 1070-1073 (2003). (Pubitemid 36513295)
7. Mauss S, Berger F, Schmutz G: Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 19(1), 93-95 (2005). (Pubitemid 40111024)
8. Peyriere H, Reynes J, Rouanet I et al.: Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J. Acquir. Immune Defic. Syndr. 35(3), 269-273 (2004). (Pubitemid 38280652)
9. Rifkin B, Perazella M: Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am. J. Med. 117(4), 282-284 (2004). (Pubitemid 39092726)
10. Verhelst D, Monge M, Meynard JL et al.: Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am. J. Kidney Dis. 40(6), 1331-1333 (2002). (Pubitemid 35403147)
11. Cihlar T, Birkus G, Greenwalt D, Hitchcock M: Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antiviral Res. 54(1), 37-45 (2002). (Pubitemid 34219173)
12. Birkus G, Hitchcock MJ, Cihlar T: Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 46(3), 716-723 (2002). (Pubitemid 34157656)
13. Reichel V, Masereeuw R, van den Heuvel JJ, Miller DS, Fricker G: Transport of a fluorescent cAMP analog in teleost proximal tubules. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293(6), R2382-R2389 (2007). (Pubitemid 350224033)
14. Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, Haefeli W: Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab. Dispos. 35(3), 340-344 (2007). (Pubitemid 46333919)
15. Liborio A, Andrade L, Pereira L, Sanches T, Shimizu M, Seguro A: Rosiglitazone reverses tenofovir-induced nephrotoxicity. Kidney Int. 74(7), 910-918 (2008).
16. + transporters and AQP2 is responsible for acyclovir-induced polyuria and hypophosphatemia. Kidney Int. 65(1), 175-183 (2004).
17. van Aubel R, Masereeuw R, Russel F: Molecular pharmacology of renal organic anion transporters. Am. J. Physiol. Renal Physiol. 279(2), F216-F232 (2000). (Pubitemid 30676977)
18. Robertson E, Rankin G: Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion. Pharmacol. Ther. 109(3), 399-412 (2006). (Pubitemid 43132819)
19. Ullrich K, Rumrich G, Gemborys M, Dekant W: Transformation and transport: how does metabolic transformation change the affinity of substrates for the renal contraluminal anion and cation transporters? Toxicol. Lett. 53(1-2), 19-27 (1990). (Pubitemid 20322435)
20. Cihlar T, Ho E, Lin D, Mulato A: Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20(4-7), 641-648 (2001). (Pubitemid 32821831)
21. Ray A, Cihlar T, Robinson KL et al.: Mechanism of active renal tubular efflux of tenofovir. Antimicrob. Agents Chemother. 50(10), 3297-3304 (2006). ■ Description of the role that multidrug resistance protein 4 plays on tenofovir renal excretion. (Pubitemid 44527501)
22. Uwai Y, Ida H, Tsuji Y, Katsura T, Inui K: Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm. Res. 24(4), 811-815 (2007). (Pubitemid 46411965)
23. Mallants R, Van OK, Van VL, Mols R, De CE, Augustijns P: Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica 35(10-11), 1055-1066 (2005). (Pubitemid 43068047)
24. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y: Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol. Pharmacol. 71(2), 619-627 (2007). (Pubitemid 46147926)
25. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG: The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. 13(3), 595-603 (2002).
26. van Aubel RA, Smeets PH, van den Heuvel JJ, Russel FG: Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am. J. Physiol. Renal. Physiol. 288(2), F327-F333 (2005).
27. Konig J, Nies AT, Cui Y, Leier I, Keppler D: Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461(2), 377-394 (1999).
28. Izzedine H, Hulot JS, Villard E et al.: Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J. Infect. Dis. 194(11), 1481-1491 (2006). ■■ Pharmacogenetic study in which the authors found that a specific haplotype at ABCC2 gene is associated with renal tubulopathy.
29. Rodriguez-Novoa S, Labarga P, Soriano V et al.: Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin. Infect. Dis. 48(11), E108-E116 (2009). ■■ Description of the association between ABCC2 -24 CC genotype and renal tubular damage.
30. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV: Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 47(3), 298-303 (2008).
31. Kiser JJ, Carten ML, Aquilante CL et al.: The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin. Pharmacol. Ther. 83(2), 265-272 (2008).
32. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV: Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J. Acquir. Immune. Defic. Syndr. 42(4), 441-449 (2006). (Pubitemid 44050891)
33. Cihlar T, Lin DC, Pritchard JB, Fuller MD, Mendel DB, Sweet DH: The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol. Pharmacol. 56(3), 570-580 (1999). (Pubitemid 29406884)
34. Hosoyamada M, Sekine T, Kanai Y, Endou H: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol. 276(1 Pt 2), F122-F128 (1999). (Pubitemid 29061732)
35. van Gelder J, Deferme S, Naesens L et al.: Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab. Dispos. 30, 924-930 (2002). (Pubitemid 34815423)
36. Madeddu G, Bonfanti P, De Socio GV et al.: Tenofovir renal safety in HIV-infected patients: results from the SCOLTA project. Biomed. Pharmacother. 62(1), 6-11(2008).
37. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G: Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin. Infect. Dis. 42(2), 283-290 (2006). (Pubitemid 43054205)
38. Viread®, package insert. Gilead Sciences, CA, USA.
39. Ray AS, Olson L, Fridland A: Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob. Agents Chemother. 48(4), 1089-1095 (2004). (Pubitemid 38405459)
40. Yarchoan R, Pluda JM, Thomas RV et al.: Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet 336(8714), 526-529 (1990). (Pubitemid 20278098)
41. Cote HC, Magil AB, Harris M et al.: Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Antivir. Ther. 11(1), 79-86 (2006). (Pubitemid 43306080)
42. Johnson M, Grinsztejn B, Rodriguez C et al.: 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 20(5), 711-718 (2006). (Pubitemid 43884298)
43. Kearney BP, Flaherty JF, Shah J: Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin. Pharmacokinet. 43(9), 595-612 (2004).
44. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK: Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J. Acquir. Immune Defic. Syndr. 43(3), 278-283 (2006). (Pubitemid 44674007)
45. Buchacz K, Brooks JT, Tong T et al.: Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy. HIV Med. 7(7), 451-456 (2006). (Pubitemid 44269812)
46. Goicoechea M, Liu S, Best B et al.: Greater tenofovir-associated renal function decline with protease inhibitor-based versus non-nucleoside reverse-transcriptase inhibitor-based therapy. J. Infect. Dis. 197(1), 102-108 (2008). (Pubitemid 351263473)
47. Izzedine H, Launay-Vacher V, Deray G: Antiviral drug-induced nephrotoxicity. Am. J. Kidney Dis. 45(5), 804-817 (2005).
48. Rollot F, Nazal EM, Chauvelot-Moachon L et al.: Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin. Infect. Dis. 37(12), E174-E176 (2003).
49. Cihlar T, Ray AS, Laflamme G et al.: Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir. Ther. 12(2), 267-272 (2007). (Pubitemid 46569912)
50. th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal, 20-22 April 2006.
51. Van Rompay KK, Brignolo LL, Meyer DJ et al.: Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy) propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob. Agents Chemother. 48(5), 1469-1487 (2004).
52. Barditch-Crovo P, Deeks SG, Collier A et al.: Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 45(10), 2733-2739 (2001). (Pubitemid 32906664)
53. Rodriguez Novoa S, Labarga P, D'Avolio A et al.: Higher tenofovir plasma levels in patients with renal tubular damage. Presented at: 16th Conference on Retrovirus and Opportunistic Infection. Denver, Canada, 8-11 February 2009.
54. Sax PE, Gallant JE, Klotman PE: Renal safety of tenofovir disoproxil fumarate. AIDS Read. 17(2), 90-92, 99-104, C3 (2007).
55. Mallal S, Nolan D, Witt C et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359(9308), 727-732 (2002). (Pubitemid 34215071)
56. Haas DW, Ribaudo HJ, Kim RB et al.: Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18(18), 2391-2400 (2004).
57. Rodriguez-Novoa S, Barreiro P, Rendón A, Jiménez-Nacher I, González-Lahoz J, Soriano V: Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin. Infect. Dis. 40(9), 1358-1361 (2005). (Pubitemid 40570249)
58. Rodriguez-Novoa S, Martin- Carbonero L, Barreiro P et al.: Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 21(1), 41-46 (2007). (Pubitemid 44912535)
59. Rotger M, Taffe P, Bleiber G et al.: Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J. Infect. Dis. 192(8), 1381-1386 (2005). (Pubitemid 41401151)
60. Martin A, Nolan D, James I et al.: Predisposition to nevirapine hypersensitibity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 19(1), 97-99 (2005). (Pubitemid 40111026)
61. Nolan D, Moore C, Castley A et al.: Tumour necrosis factor-α gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 17(1), 121-123 (2003). (Pubitemid 36106307)
62. Felley C, Morris MA, Wonkam A et al.: The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study. AIDS 18(11), 1521-1527 (2004). (Pubitemid 39037476)
63. Kallianpur AR, Hulgan T, Canter JA et al.: Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS 20(11), 1503-1513 (2006). (Pubitemid 44100211)
64. Bleasby K, Hall LA, Perry JL, Mohrenweiser HW, Pritchard JB: Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6 ). J. Pharmacol. Exp. Ther. 314(2), 923-931 (2005). (Pubitemid 41043879)
65. Itoda M, Saito Y, Soyama A et al.: Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5′-untranslated region and exon 28. Drug Metab. Dispos. 30(4), 363-364 (2002). (Pubitemid 34263818)
66. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K: Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11(2), 175-184 (2001). (Pubitemid 32216128)